Hosted on MSN1mon
Ozempic-like jab 'fails' for millions with condition, study finds
At the end of the 96-week study those taking exenatide, sold under the brand Bydureon in the UK, saw no benefits compared to the placebo group. Experts were unsure why this was the case ...
Medscape1d
Short-term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
Indiatimes1mon
Ozempic-like drug fails to treat Parkinson's disease in new study; here's what the scientists said
a type 2 diabetes treatment made by AstraZeneca and available under the brand name Byetta, or with a placebo. While it is one of the GLP-1 receptor agonists, Exenatide is not as powerful weight ...